Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Accenture
McKinsey
Chinese Patent Office
QuintilesIMS
Fish and Richardson
US Army
Queensland Health
Argus Health
Novartis

Generated: October 22, 2017

DrugPatentWatch Database Preview

Bausch And Lomb Company Profile

« Back to Dashboard

What is the competitive landscape for BAUSCH AND LOMB, and what generic alternatives to BAUSCH AND LOMB drugs are available?

BAUSCH AND LOMB has seventy-five approved drugs.

There are twenty-two US patents protecting BAUSCH AND LOMB drugs.

There are one hundred and forty-two patent family members on BAUSCH AND LOMB drugs in twenty-two countries and forty-eight supplementary protection certificates in eleven countries.

Summary for Applicant: Bausch And Lomb

International Patents:142
US Patents:22
Tradenames:64
Ingredients:53
NDAs:75
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb
LOTEMAX
loteprednol etabonate
OINTMENT;OPHTHALMIC200738-001Apr 15, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Bausch And Lomb
RETISERT
fluocinolone acetonide
IMPLANT;INTRAVITREAL021737-001Apr 8, 2005RXYesYes► Subscribe► SubscribeY ► Subscribe
Bausch And Lomb Inc
IPRATROPIUM BROMIDE
ipratropium bromide
SOLUTION;INHALATION075835-001Oct 15, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Bausch And Lomb
ALBUTEROL SULFATE
albuterol sulfate
SOLUTION;INHALATION075358-001Mar 29, 2000DISCNNoNo► Subscribe► Subscribe► Subscribe
Bausch And Lomb
TIMOLOL MALEATE
timolol maleate
SOLUTION/DROPS;OPHTHALMIC074778-001Mar 25, 1997ATRXNoNo► Subscribe► Subscribe► Subscribe
Bausch And Lomb
PROLENSA
bromfenac sodium
SOLUTION/DROPS;OPHTHALMIC203168-001Apr 5, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Bausch And Lomb
PROLENSA
bromfenac sodium
SOLUTION/DROPS;OPHTHALMIC203168-001Apr 5, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Bausch And Lomb
DORZOLAMIDE HYDROCHLORIDE
dorzolamide hydrochloride
SOLUTION/DROPS;OPHTHALMIC090143-001Jun 25, 2009ATRXNoNo► Subscribe► Subscribe► Subscribe
Bausch And Lomb
GENTAMICIN SULFATE
gentamicin sulfate
SOLUTION/DROPS;OPHTHALMIC064048-001May 11, 1994ATRXNoYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bausch And Lomb

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb
ZYLET
loteprednol etabonate; tobramycin
SUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 2004► Subscribe► Subscribe
Bausch And Lomb Inc
XIBROM
bromfenac sodium
SOLUTION/DROPS;OPHTHALMIC021664-001Mar 24, 2005► Subscribe► Subscribe
Bausch And Lomb
LOTEMAX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998► Subscribe► Subscribe
Bausch And Lomb
VITRASERT
ganciclovir
IMPLANT;IMPLANTATION020569-001Mar 4, 1996► Subscribe► Subscribe
Bausch And Lomb
ALREX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020803-001Mar 9, 1998► Subscribe► Subscribe
Bausch And Lomb
LOTEMAX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998► Subscribe► Subscribe
Bausch And Lomb Inc
LOTEMAX
loteprednol etabonate
GEL;OPHTHALMIC202872-001Sep 28, 2012► Subscribe► Subscribe
Bausch And Lomb
ALREX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020803-001Mar 9, 1998► Subscribe► Subscribe
Bausch And Lomb
LOTEMAX
loteprednol etabonate
SUSPENSION/DROPS;OPHTHALMIC020583-001Mar 9, 1998► Subscribe► Subscribe
Bausch And Lomb
ZYLET
loteprednol etabonate; tobramycin
SUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BAUSCH AND LOMB drugs

Drugname Dosage Strength Tradename Submissiondate
bepotastine besilate
Ophthalmic Solution1.5%
BEPREVE
9/9/2013
bromfenac sodium
Ophthalmic Solution0.07%
PROLENSA
7/26/2013
timolol maleate
Ophthalmic Solution0.5%
ISTALOL
10/19/2012

Non-Orange Book Patents for Bausch And Lomb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,056,893Topical treatment for prevention of ocular infections► Subscribe
8,497,304Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid► Subscribe
6,307,052 Acid-addition salts of optically active piperidine compound and process for producing the same► Subscribe
8,252,307Method for treating and/or preventing retinal diseases with sustained release corticosteroids► Subscribe
7,282,589Acid addition salt of optically active piperidine compound and process for preparing the same► Subscribe
8,883,825Aqueous liquid preparations and light-stabilized aqueous liquid preparations► Subscribe
6,239,113 Topical treatment or prevention of ocular infections► Subscribe
6,569,443 Topical treatment or prevention of ocular infections► Subscribe
7,732,415Topical treatment or prevention of ocular infections► Subscribe
7,749,970Topical treatment of prevention of ocular infections► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bausch And Lomb Drugs

Country Document Number Estimated Expiration
Austria528003► Subscribe
China1612734► Subscribe
South Korea101016595► Subscribe
Germany69839152► Subscribe
European Patent Office1525884► Subscribe
South Korea20030092108► Subscribe
Mexico2011009758► Subscribe
Japan3631748► Subscribe
Hong Kong1083468► Subscribe
Malaysia118016► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bausch And Lomb Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
780Luxembourg► SubscribePRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
C/GB99/043United Kingdom► SubscribePRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
C0111Belgium► SubscribePRODUCT NAME: LATANOPROSTUM; NAT. REGISTRATION NO/DATE: 277 IS 271 F 13 19970617; FIRST REGISTRATION: SE 12716 1996071
14/041Ireland► SubscribePRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
2016 00031Denmark► SubscribePRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
80016Netherlands► SubscribePRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
2016000049Germany► SubscribePRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
90018-0Sweden► SubscribePRODUCT NAME: BROMFENAK; REG. NO/DATE: EU/1/11/692/001 20110518
0683Netherlands► SubscribePRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
90031-1Sweden► SubscribePRODUCT NAME: LATANOPROST
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Covington
Federal Trade Commission
Colorcon
Citi
Harvard Business School
Julphar
Argus Health
AstraZeneca
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot